εταιρικά νέα για Flexible Containment: Modular Solutions for Potent Compound Handling

1. Containment Performance

Modern flexible isolators achieve operator exposure levels below0.05ug/m3  (OEB 5), meeting ISPE SMEPAC and NIOSH guidelines for highly potent active pharmaceutical ingredients (HPAPIs).

2. Modularity Benefits

• Rapid deployment (typically 4-8 weeks vs. 6-12 months for rigid systems)
• Relocatable across manufacturing sites
• Scalable capacity for clinical to commercial production
• Configurable for various unit operations (dispensing, sampling, milling)

3. Operational Efficiency

Flexible systems reduce cleaning validation burden, minimize facility footprint, and lower HVAC classification requirements compared to traditional hard-wall isolators.

Application Areas:

• Dispensing & Sampling of HPAPIs and cytotoxic compounds
• API Manufacturing for oncology and hormonal products
• Tablet Coating & Milling operations
• Clinical Trial Material preparation
• Contract Manufacturing with frequent product changeovers

• Conclusion

  Flexible containment represents the optimal balance between engineering control .operational flexibility and captial efficiency  for modern pharmaceutical manufacturing. As the pipeline of HPAPIs continues to expand—particularly in oncology and targeted therapies—modular flexible containment solutions are becoming the industry standard, enabling manufacturers

  to safely handle increasingly potent molecules while maintaining the agility required for personalized medicine and small-batch production